Tigermed (泰格医疗) A+H: Past A+H Listings Suggest Upside Might Be Limited
376 Views27 Jul 2020 15:34
Tigermed, the largest China-based clinical CRO company, launched book building today to raise up to USD 1.4 bn to list in Hong Kong.
In our...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
- Tigermed (泰格医疗) A+H: Past A+H Listings Suggest Upside Might Be Limited27 Jul 2020
- Tigermed (泰格医疗) A+H: PHIP Updates and Thoughts on Valuation20 Jul 2020
- Tigermed (泰格医疗) A+H Listing: Hot Deal of the Best China Clinical-CRO Play26 Apr 2020
x